Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

30 results
Display

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors

Choi JY, Na JO

Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study

Kim J, Lee K, Kim J, Lee JM, Kim NY, Lee MS, Ji E

Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis

Lee HY, Jun DW, Kim HJ, Oh H, Saeed WK, Ahn H, Cheung RC, Nguyen MH

BACKGROUND/AIMS: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The utility of ezetimibe therapy in nonalcoholic fatty liver disease

Jun BG, Cheon GJ

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)

Hwang YC

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)

Sohn TS

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lipid-Lowering Therapy Guidelines

Lee SH

The major guidelines for lipid-lowering therapy (LLT) have been revised recently. Although “higher cardiovascular risk-aggressive LLT with greater absolute clinical benefit” is the main idea underlying all guidelines, there are...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus

Hwang YC, Jun JE, Jeong IK, Ahn KJ, Chung HY

BACKGROUND: The apolipoprotein B/A1 (apoB/A1) ratio is a stronger predictor of future cardiovascular disease than is the level of conventional lipids. Statin and ezetimibe combination therapy have shown additional cardioprotective...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis

Hong N, Lee YH, Tsujita K, Gonzalez J, Kramer CM, Kovarnik T, Kouvelos G, Suzuki H, Han K, Lee CJ, Park SH, Lee BW, Cha BS, Kang ES

BACKGROUND: Ezetimibe-statin combination therapy has been found to reduce low density lipoprotein cholesterol levels and the risk of major adverse cardiovascular events (MACEs) in large trials. We sought to examine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
What Do We Get from Recent Statin and CETP Inhibitors Trials?

Kim BJ

Recent clinical trials and meta-analyses have indicated that high-intensive statin treatment lowers low-density lipoprotein cholesterol (LDL-C) levels and reduces the risk of nonfatal cardiovascular (CV) events compared with moderate-intensity statin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects

Hwang I, Park SI, Lee S, Lee B, Yu KS, Jeon JY, Kim MG

This study aimed to compare the pharmacokinetics of fixed-dose combination (FDC) tablet of rosuvastatin 20 mg/ezetimibe 10 mg with that of concurrent administration of individual rosuvastatin 20 mg tablet and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Statin Intolerance: an Overview of the Current Status and Possible Treatment Options

Suh S, Jung CH, Hong SJ, Kim JS, Choi SH

Lowering serum low-density lipoprotein cholesterol (LDL-C) is the mainstay for reduction of risk of cardiovascular disease (CVD), the second most common cause of death in Korea. The 2015 Korean guidelines...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers

Park J, Kim CO, Jin BH, Yang S, Park MS, Hong T

Atorvastatin and ezetimibe are frequently co-administered to treat patients with dyslipidemia for the purpose of low-density lipoprotein cholesterol control. However, pharmacokinetic (PK) drug interaction between atorvastatin and ezetimibe has not...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Simvastatin/Ezetimibe Therapy for Recalcitrant Alopecia Areata: An Open Prospective Study of 14 Patients

Choi JW, Suh DW, Lew BL, Sim WY

BACKGROUND: Simvastatin belongs to the statin family, whose members have immunomodulatory activities. Ezetimibe have synergetic effects when co-administered with simvastatin. In several case reports, alopecia totalis and alopecia universalis were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy

Lee JB, Kim GS, Cho HN

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early Effects of Intensive Lipid-Lowering Treatment on Plaque Characteristics Assessed by Virtual Histology Intravascular Ultrasound

Lee JH, Shin DH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK

PURPOSE: The effects of short-term intensive lipid-lowering treatment on coronary plaque composition have not yet been sufficiently evaluated. We investigated the influence of short-term intensive lipid-lowering treatment on quantitative and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Management of Dyslipidemia according to the 2015 Treatment Guideline for Diabetes: Controversies and Issues to Resolve

Moon MK

The 2015 Treatment Guideline for Diabetes recommends statin therapy as the mainstay of management for dyslipidemia in order to lower low-density lipoprotein (LDL) cholesterol and thus prevent cardiovascular disease. It...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Glucotoxicity Protecting Effect of Ezetimibe in Pancreatic Beta Cells via Inhibition of CD36

Yoon JS, Moon JS, Kim YW, Won KC, Lee HW

Inhibition of CD36, a fatty acid transporter, has been reported to prevent glucotoxicity and ameliorate high glucose induced beta cell dysfunction. Ezetimibe is a selective cholesterol absorption inhibitor that blocks...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Combination pharmacotherapy in lipid management

Lee SH

Latest guidelines on lipid management recommend statins as the first-line therapy. Because limited evidence is available on cardiovascular outcomes with varying statin-nonstatin combinations, recommendation levels for these regimens have been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Pretreatment of Ezetimibe/Simvastatin on Arterial Healing and Endothelialization after Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model

Sim DS, Jeong MH, Park DS, Kim JH, Lim KS, Kim HK, Kim SS, Cho JY, Jeong HC, Park KH, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC

BACKGROUND AND OBJECTIVES: We sought to evaluate the effect of the early use of ezetimibe/simvastatin (Vytorin(R)) on arterial healing and endothelialization after the implantation of a drug-eluting stent (DES) in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr